Walt Whitley, OD, MBA, FAAO, & Selina McGee, OD, FAAO The journey of the dry eye patient can be challenging. They often go to multiple practitioners and try several at-home remedies in an attempt to have their condition taken seriously and get some relief. In this podcast, Selina McGee, OD, FAAO, joins Walt Whitley, OD, MBA, FAAO to discuss the importance of building trust to empower dry eye patients in order to confidently take back control of their condition, as well as how EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%*—the first FDA-approved steroid for the short-term treatment (up to two weeks) of the signs and symptoms of DED—and its AMPPLIFY® technology may benefit their patients.

Preeya Gupta, MD, & Cynthia Matossian, MD, FACS, ABES The journey of the dry eye patient can be challenging. They often go to multiple practitioners and try several at-home remedies in an attempt to have their condition taken seriously and get some relief. In this podcast, Cynthia Matossian, MD, FACS, ABES joins Preeya Gupta, MD to discuss the importance of building trust to empower dry eye patients to take back control in order to better manage their condition, as well as how EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%*—the first FDA-approved steroid for the short-term treatment (up to two weeks) of the signs and symptoms of DED—and its AMPPLIFY® technology may benefit their patients.

This podcast session will explore a fresh approach to treating Dry Eye Disease (DED) and the challenges faced by your current and future patients. We are all aware that ODs play an important role as first responders in how care is delivered to DED patients. At Kala, we have discovered through extensive market research that Dry Eye Disease does not always present as continuous signs and symptoms, rather it is punctuated by exacerbating episodes or “speed bumps” called Dry Eye Flares. Join Walt Whitley, OD, MBA, FAAO in his conversation with Margie Recalde, OD, FAAO as they navigate Dry Eye Flares along with the role of inflammation in identifying patients who might benefit from a different treatment of DED.

This podcast session will explore a fresh approach to treating Dry Eye Disease (DED) and the challenges faced by your current and future patients. We are all aware that MDs play an important role as first responders in how care is delivered to DED patients. At Kala, we have discovered through extensive market research that Dry Eye Disease does not always present as continuous signs and symptoms, rather it is punctuated by exacerbating episodes or “speed bumps” called Dry Eye Flares. Join Preeya Gupta, MD in his conversation with Lisa Nijm, MD as they navigate Dry Eye Flares along with the role of inflammation in identifying patients who might benefit from a different treatment of DED.